- Affiliate Associate Professor, Global Health
- VP, Formulations
Select from the following:
Dr. Christopher Fox is the Vice President of Formulations at the Infectious Disease Research Institute (IDRI) and oversees the research and development of vaccine adjuvants. With over 15 years of product development experience in adjuvants and formulations including cGMP manufacture and clinical testing, and more than 80 peer-reviewed papers, Dr. Fox has established himself as an expert in this field. He is the editor of a volume from the Springer Methods in Molecular Biology Series entitled “Vaccine Adjuvants: Methods and Protocols” published in 2017 and has served as the principal investigator of multiple grants and contracts from US government agencies and foundations. He has also directed technology transfer of adjuvant formulation manufacturing to institutes in India, Brazil, South Africa, and Romania. Dr. Fox was awarded the 2015 Pioneers in Global Health Rising Leader Award from the Washington Global Health Alliance.
- PhD (University of Utah)
- BS (Utah State University)
- Biodefense Infectious Diseases
- Delivery Logistics
- Diarrheal Diseases
- Drug and Vaccine Development
- Education and Training
- Infectious Diseases
- Innate Immunity
- Neglected Diseases, Tropical Medicine (incl. Parasites)
- Pharmaceutical Science
- Respiratory Disease
- Waterborne Diseases
- Zoonotic Diseases and Animal Health
Abhyankar, M. M.; Orr, M. T.; Lin, S.; Suraju, M. O.; Simpson, A.; Blust, M.; Pham, T.; Guderian, J. A.; Tomai, M. A.; Elvecrog, J.; Pedersen, K.; Petri, W. A. Jr.; Fox, C. B. “Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica,” NPJ Vaccines, 2018, 3:22.
Methods in Molecular Biology: Vaccine Adjuvants; Fox, C. B., Editor; Springer, New York, 2017.
Fox, C. B.; Orr, M. T.; Van Hoeven, N.; Parker, S. C.; Mikasa, T. J.; Phan, T.; Beebe, E. A.; Nana, G. I.; Joshi, S. W.; Tomai, M. A.; Elvecrog, J.; Fouts, T. R.; Reed, S. G. “Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: a formulation approach,” Journal of Controlled Release, 2016, 244:98-107.
Fox, C. B.; Huynh, C.; O’Hara, M. K.; Onu, A. “Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania,” Vaccine, 2013, 31:1633-1640.
Key roles of adjuvants in modern vaccines. Reed SG, Orr MT, Fox CB. Nat Med. 2013 Dec;19(12):1597-608. doi: 10.1038/nm.3409. Epub 2013 Dec 5. Review.